Bristol-Myers Squibb Company (BMY)
Healthcare · Drug Manufacturers - General · Data as of 2026-09-01
Bottom line
BMY is trading at a discount to its history, in the middle of its recent price range, and recent volume suggests money flowing in. Historically, this combination has been a favourable starting point for further research. Past patterns are not a guarantee of future results.
Valuation — Trading at a discount to its history (Green)
BMY trades at 15× earnings, below its own 5-year average of 18× and below similar healthcare companies we track (29×, 52 peers). Historically this has been on the cheaper side for the stock. It also generates strong cash: a free-cash-flow yield of about 8%. One caution: revenue has been shrinking, so the low multiple may reflect a weakening business rather than a bargain. Its current multiple sits around the 17th percentile of its own last five years — toward the low end of its own range. Its fundamentals scored 9 of 9 on a standard year-over-year quality checklist — most of the underlying trends improved last fiscal year.
Price zones — In the middle of its recent range (Yellow)
At $66.92, the stock sits between its recent support and resistance levels. Over the past year BMY has traded between $42.52 and $68.64; its historical support zone sits near $62.17 and resistance near $68.64. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $42.52–$68.64 · 50-day average $62.17 · 200-day average $57.83
Money flow — Money is flowing in (Green)
Recent trading in BMY shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 3.3× volume on down days over the last 30 sessions.
About the company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular…
一句话结论
BMY 相对自身历史处于折价水平，处于近期价格区间的中部，近期成交量显示资金正在流入。从历史来看，这样的组合是一个值得进一步研究的有利起点。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于折价水平
BMY 目前的市盈率为 15×，低于其自身 5 年平均的 18×，并且低于我们追踪的同类Healthcare公司（29×，52 家）。从历史来看，这属于该股较便宜的一侧。它同时产生充沛的现金：自由现金流收益率约为 8%。有一点需要留意：营收一直在萎缩，因此较低的估值倍数可能反映的是业务转弱，而非便宜。它当前的估值倍数大约位于自身过去五年分布的第 17 百分位——处于自身区间的偏低位置。在一套标准的逐年基本面核对清单上，它 9 项中通过了 9 项——上一财年多数底层趋势在改善。
价格区间 — 处于近期区间的中部
目前价格为 $66.92，位于其近期的支撑位与阻力位之间。过去一年 BMY 的价格在 $42.52 到 $68.64 之间波动；其历史支撑区在 $62.17 附近，阻力区在 $68.64 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流入
BMY 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 3.3×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.